Stockscreener 앱 받기
19.75
1.55%
-0.31
시간 외 거래:
20.00
0.25
+1.27%
전일 마감가:
$20.06
열려 있는:
$19.88
하루 거래량:
1.37M
Relative Volume:
0.89
시가총액:
$3.13B
수익:
$1.27M
순이익/손실:
$-512.54M
주가수익비율:
-6.6518
EPS:
-2.9691
순현금흐름:
$-422.10M
1주 성능:
-4.59%
1개월 성능:
-2.42%
6개월 성능:
+54.90%
1년 성능:
+33.27%
1일 변동 폭
$18.93
$20.19
1주일 범위
$18.93
$21.42
52주 변동 폭
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
19.75 | 3.18B | 1.27M | -512.54M | -422.10M | -2.9691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
EV Market: How sensitive is Denali Therapeutics Inc to inflationProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts - Yahoo Finance
Price-Driven Insight from (DNLI) for Rule-Based Strategy - Stock Traders Daily
Pharma News: Is Denali Therapeutics Inc stock suitable for long term investing2026 Levels & Weekly Stock Breakout Alerts - baoquankhu1.vn
Holocene Advisors LP Grows Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
1,000,000 Shares in Denali Therapeutics Inc. $DNLI Purchased by Foresite Capital Management VI LLC - MarketBeat
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build - MarketBeat
250,000 Shares in Denali Therapeutics Inc. $DNLI Bought by Boxer Capital Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Yahoo Finance
DNLI News & Events - Intellectia AI
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
DNLI: Imminent FDA decision and expanding pipeline highlight strong clinical and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed? - simplywall.st
HC Wainwright Issues Positive Forecast for DNLI Earnings - MarketBeat
Rafferty Asset Management LLC Buys 60,624 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Market Wrap: Can Denali Therapeutics Inc scale operations efficientlyJuly 2025 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
TD Asset Management Inc Trims Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Fisher Asset Management LLC Increases Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration - Sahm
Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing The 56.80% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from BTIG - The Globe and Mail
Jefferies reiterates Denali stock Buy rating on gene therapy outlook By Investing.com - Investing.com Canada
Jefferies reiterates Denali stock Buy rating on gene therapy outlook - Investing.com India
BTIG Research Increases Denali Therapeutics (NASDAQ:DNLI) Price Target to $36.00 - MarketBeat
Denali Therapeutics Inc. Trade Ideas — GETTEX:4DN - TradingView
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - National Today
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative? - simplywall.st
Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Denali Therapeutics Q4 net loss deepens - TradingView
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones - Stock Titan
BRIEF-Denali Therapeutics Q4 Operating Expenses USD 137.365 Million - TradingView
Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan
Volume Recap: Is Denali Therapeutics Inc. a turnaround storyMarket Weekly Review & Weekly Chart Analysis and Guides - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Strong Buy Ratings Signal a 57% Potential Upside - DirectorsTalk Interviews
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):